Surgical cytoreduction for recurrent epithelial ovarian cancer

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2013, Pages

  Al Rawahi, Thuria ^a   Lopes, Alberto D ^b   Bristow, Robert E ^c   Bryant, Andrew ^d   Elattar, Ahmed ^e   Chattopadhyay, Supratik ^f   Galaal, Khadra ^b  

^a ROYAL HOSPITAL   (Oman)

^b ROYAL CORNWALL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e CITY HOSPITAL   (United Kingdom)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CYTOREDUCTIVE SURGERY; HEALTH IMPACT ASSESSMENT; HIGH RISK POPULATION; HUMAN; META ANALYSIS; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SURVIVAL ANALYSIS; SYSTEMATIC REVIEW; TUMOR VOLUME; ADULT; FEMALE; MORTALITY; NEOPLASM; OVARIAN EPITHELIAL CANCER; OVARY TUMOR; PATHOLOGY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENT;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TUMOR BURDEN;

EID: 84875546218     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008765.pub3     Document Type: Review

References (66)

1. Ayhan A, Gultekin M, Taskiran C, Aksan G, Celik N, Dursun P, et al.The role of secondary cytoreduction in the treatment of ovarian: Hacettepe University experience. American Journal of Obstetrics and Gynaecology 2006;194:49-56.
2. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al.Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006;106(9):1933-9.
3. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000;88(1):144-53.
4. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl Si, et al.Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Annals of Surgical Oncology 2006;13(12):1702-10.
5. Oksefjell H, Sandstad B, Tropé C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2009;20(2):286-93.
6. Salani R, Santillan A, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Armstrong DK, et al.Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer. Cancer 2007;109(4):685-91.
7. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecologic Oncology 2001;83:504-12.
8. Tian WJ, Jiang R, Cheng X, Tang J, Xing Y, Zang RY. Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1 - 1 cm after secondary cytoreduction. Journal of Surgical Oncology 2010;101:244-50.
9. Zang RY, Zhang ZY, Li ZT, Chen J, Tang MQ, Liu Q, et al.Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. Journal of Surgical Oncology 2000;75(1):24-30.
10. Benedetti Panici P, De Vivo A, Bellati F, Manci N, Perniola G, Basile S, et al.Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Annals of Surgical Oncology 2006;14(3):1136-42.
11. Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elasoff RM. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstetrics & Gynecology 1983;61(2):189-93.
12. Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, et al.Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecologic Oncology 2003;90(3):519-28.
13. Bristow RE, Peiretti M, Gerardi M, Zanagnolo V, Ueda S, Diaz-Montes T, et al.Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Gynecologic Oncology 2009;114(2):173-7.
14. Eisenkop S M, Friedman R L, Wang H J. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer 1995;76(9):1606-14.
15. Gadducci A, Lacconi P, Cosio S, Fanucchi A, Cristofani R, Riccardo Genazzani A. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecologic Oncology 2000;79(3):344-9.
16. Goto T, Takano M, Watanabe A, Miyamoto M, Kato M, Hirata J, et al.Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers. International Journal of Gynecological Cancer 2011;21:263-8.
17. Gronlund B, Lundvall L, Christensen IJ, Knudsen JB, Hogdall C. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. European Journal of Surgical Oncology 2005;31(1):67-73.
18. Gungor M, Ortak F, Arvas M, Kosebay D, Sonmezer M, Kose K. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecologic Oncology 2005;97(1):74-9.
19. Helm CW, Randall-Whitis L, Martin RS 3rd, Metzinger DS, Gordinier ME, Parker LP, et al.Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecologic Oncology 2007;105(1):90-6.
20. Karam AK, Santillan A, Bristow RE, Giuntoli II R, Gardner GJ, Cass I, et al.Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecologic Oncology 2007;104(2):377-80.
21. Landoni F, Pellegrino A, Cormio G, Milani R, Maggioni A, Mangioni C. Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy. Acta Obstetricia et Gynecologica Scandinavica 1998;77(2):233-7.
22. Matsumoto A, Higuchi T, Yura S, Mandai M, Kariya M, Takakura K, et al.Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy. The Journal of Obstetrics and Gynaecology Research 2006;32(6):580-7.
23. Morris M, Gershenson DM, Wharton JT, Copeland LJ, Edwards CL, Stringer CA. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecologic Oncology 1989;34(3):334-8.
24. Munkarah A, Levenback C, Wolf JK, Bodurka-Bevers D, Tortolero-Luna G, Morris RT, et al.Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecologic Oncology 2001;81(2):237-41.
25. Park JY, Seo SS, Kang S, Lee KB, Yi LS, Seong CH, et al.The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecologic Oncology 2006;103(3):977-84.
26. Tay EH, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstetrics and Gynecology 2002;99(6):1008-13.
27. Tebes Stephen J, Sayer Robyn A, Palmer James M, Tebes Christine C, Martino Martin A, Hoffman Mitchel S. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecologic Oncology 2007;106(3):482-7.
28. Vaccarello L, Rubin SC, Vlamis V, Wong G, Jones WB, Lewis JL, et al.Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecologic Oncology 1995;57(1):61-5.
29. van der Vange N, van Goethem AR, Zoetmulder FAN, Kaag MM, van de Vaart PJM, ten Bokkel Huinink WW, et al.Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. European Journal of Surgical Oncology (EJSO) 2000;26(7):663-8.
30. Zang R-Y, Zhang Z-Y, Li Z-T, Cai S-M, Tang M-Q, Chen J, et al.Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. European Journal of Surgical Oncology (EJSO) 2000;26(8):798-804.
31. Zang R-Y, Li Z-T, Zhang Z-Y, Cai S-M. Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study. International Journal of Gynecological Cancer 2003;13(4):419-27.
32. Zang RY, Li ZT, Tang J, Cheng X, Cai SM, Zhang ZY, et al.Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?. Cancer 2004;100(6):1152-61.
33. Zanon C, Clara R, Chiappino I, Bortolini M, Cornaglia S, Simone P, et al.Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World Journal of Surgery 2004;28(10):1040-5.
34. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Seminars in Oncology 1998;25:326-34.
35. Bookman MA, Malmström H, Bolis G, Gordon A, Lissoni A, Krebs JB, et al.Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. Journal of Clinical Oncology 1998;16(10):3345-52.
36. Bristow RE, Tomacruz RS, Armstrong DK, Timble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology 2002;20:1248-59.
37. Burke TW, Morris M. Secondary cytoreductive surgery for ovarian cancer. Obstetrics and Gynecology Clinics of North America 1994;21:167-78.
38. Common Terminology Criteria for Adverse Events v3.0. www.eortc.be/services/doc/ctc/ctcaev3.pdf (accessed 23 January 2013).
39. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
40. Delgado G, Oram DH, Petril ES. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecologic Oncology 1984;18:293-8.
41. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
42. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD007565.pub2]
43. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al and the EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Annals of Oncology 2003;14 Suppl 5:v61-v118.
44. Galaal K, Naik R, Bristow RE, Patel A, Bryant A, Dickinson HO. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2010, Issue 6. [DOI: 10.1002/14651858.CD007822.pub2]
45. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. globocan.iarc.fr (accessed 23 January 2013).
46. Goff BA, Mander L, Muntz HG. Ovarian carcinoma diagnosis. Cancer 2000;89(10):2068-75.
47. Gonzalez-Martin AA, CIavo E, Bover I, Rubio J, Arcusa A, Casado A. Randomized phase II study of carboplatin versus paclitaxel-carboplatin in platinum sensitive recurrent advanced ovarian carcinoma with assessment of quality of life. Proceedings of the American Society of Clinical Oncology 2003;22:abs 1812.
48. Hacker NF, Berek JS, Lagasse CD, Neiberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstetrics and Gynecology 1983;61:413-20.
49. Hannibal CG. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five year relative survival. Acta Obstetricia et Gynecologica Scandinavica 2008;87(12):1353-60.
50. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
51. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
52. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al.The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with sub optimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology 1994;70:974-80.
53. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents, Volume VIII. IARC Scientific Publication 2002; No. 155 2002.
54. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T. Cancer statistics. CA: A Cancer Journal for Clinicians 2008;58:71-96.
55. Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, et al.Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. Journal of Clinical Oncology 2004;22(15):3120-5.
56. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecologic Oncology 2004;95(2):273-80.
57. Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, Barakat R, Markman M, Randall M editor(s). Principles and Practice of Gynecologic Oncology. 4th Edition. Philadelphia, PA: Lippincott-Raven Publishers, 2005:895-987.
58. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
59. Parmar MK, Ledermann JA, Colombo N, du Bios A, Delaloye JF, Kristensen GB. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer. the ICON4/AGO-OVAR-2-2 trial. Lancet 2003;361:2099-106.
60. Piver MS, Lele SB, Marchetti DL, Baker TR, Tsukaso Y, Emrich LJ. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in Stage III and IV ovarian carcinoma. Journal of Clinical Oncology 1988;6:983-9.
61. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
62. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology. Vol. Fascicle 23 3rd series, Washington, DC: Armed Forces Institute of Pathology, 1998:1-168.
63. Shepherd JH. Revised FIGO staging for gynaecological cancer. British Journal of Obstetrics and Gynaecology 1989;96(8):889-92.
64. Smith LH, Morris CR, Yasmeen S. Ovarian cancer: can we make the clinical diagnosis earlier?. Cancer 2005;104(7):1398-407.
65. Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. European Journal of Cancer 2011;47 Suppl 3:S88-92.
66. Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, et al.Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006;107(1):83-9.